Pfizer to shut two out of three manufacturing plants in UK

pharmafile | November 9, 2016 | News story | Manufacturing and Production, Research and Development Pfizer, UK, manufacturing, production, sites 

Pfizer has announced that it will close two of the three manufacturing plants it still holds in the UK. The decision places at risk 370 jobs.

The two sites planned for closure are The Park Royal site in London, which is planned for closure by May 2017 and will see 100 employees potentially lose their jobs. The other site, based in Havant, in Portsmouth, will close by 2020 and will potentially see 270 job losses. The manufacturing plants will be moved to site based in Puurs, Belgium.

Pfizer were keen to stress that the closures are not related to the referendum decision leading to Brexit. A spokesperson, speaking to the Telegraph, commented that “These decisions have nothing to do with Brexit…This review process has been going on since 2010 and the team just felt there were more production capabilities at the site in Belgium to support future demand and to ensure we can support the supply chain.”

Pfizer stressed that they would attempt to find ways of reducing in job losses from the sites. The decision to close the sites was also based on the age of the facilities, particularly that of The Park Royal site, which was acquired alongside Hospira in September of this year.

 Ben Hargreaves

Related Content


Novo Nordisk invests 42bn Danish kroner to expand facilities in Kalundborg, Denmark

Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing …

ViroCell and GOSH gain MHRA manufacturing approval

ViroCell Biologics has announced that it can now manufacture and export viral vectors from Great …

CDC Advisory Committee recommends Pfizer’s RSV vaccine

Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee …

Latest content